From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway.

ABSTRACT:

Background and purpose

Norway has one of the highest rates of cutaneous melanoma (CM) incidence and mortality globally. Immune checkpoint inhibitor (ICI) therapy for CM was introduced between 2014 and 2017 to improve treatment and patient prognosis, but knowledge about its clinical usage is limited. This study investigates patient's characteristics and treatment patterns in real-world practice compared to clinical trial results.

Material and methods

All adult (≥18) CM patients treated with ICI therapy in Norway from 2014 to 2021 were included, utilizing high-coverage data from multiple national registries to describe patients' health, socioeconomic factors, and treatment management, stratified by first ICI therapy. We compared patient and tumour characteristics with findings

SUBMITTER: Reis Costa D 

PROVIDER: S-EPMC11681278 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature